Dr Aram Mangasarian has replaced Iain Buchanan as Chief Executive at German biotechnology company Noxxon Pharma. Buchanan will join the company's supervisory board as a Non-executive Director.
Mangasarian joined Noxxon in May 2010 and since then has led business development as Chief Business Officer, working with Buchanan on the Executive Committee.
Buchanan, who took up the role of CEO in September 2010, steps down from the operational day-to-day business, but will continue to work with the management team before he rejoins the supervisory board.
Mangasarian has more than 15 years of experience in biotechnology and pharmaceutical business development. He began his career at ExonHit Therapeutics (now Diaxonhit), in May 2000, eventually heading the business development function as Vice-President.
He joined Novexel as Vice-President Business Development in October 2005.
Noxxon Pharma is a clinical-stage biopharmaceutical company developing Spiegelmers, a novel class of proprietary nucleic acid-based therapeutic agents built on a backbone of mirror-image nucleotides. Spiegelmers are chemically synthesised L-stereoisomer oligonucleotide aptamers, an immunologically passive alternative to antibodies.
